P500 Post-marketing safety experience of vedolizumab in patients receiving concomitant treatment with other biologics

P500 Post-marketing safety experience of vedolizumab in patients receiving concomitant treatment with other biologics

Detalles Bibliográficos
Main Authors:	Cohen, R, Bhayat, F, Blake, A, Travis, S
Formato:	Conference item
Publicado:	Oxford University Press 2019

Títulos similares

Post-marketing experience of vedolizumab: Pneumonia and other respiratory tract infections
por: Bhayat, F, et al.
Publicado: (2017)

Post-marketing experience of vedolizumab in inflammatory bowel disease: analysis of pneumonia and other respiratory tract infections
por: Bhayat, F, et al.
Publicado: (2017)

Post-marketing safety experience of vedolizumab in older patients with inflammatory bowel disease
por: Travis, S, et al.
Publicado: (2018)

The safety profile of vedolizumab in ulcerative colitis and Crohn's disease: 4 years of global post-marketing data
por: Cohen, R, et al.
Publicado: (2019)

Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data
por: Card, T, et al.
Publicado: (2019)

Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data
por: Card, T, et al.
Publicado: (2019)

Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment: clinical trial experience
por: Feagan, B, et al.
Publicado: (2017)

Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment for inflammatory bowel disease: clinical trial experience
por: Feagan, B, et al.
Publicado: (2017)

Respiratory tract infections in patients with inflammatory bowel disease: safety analyses from vedolizumab clinical trials
por: Feagan, BG, et al.
Publicado: (2018)

Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease.
por: Bye, W, et al.
Publicado: (2017)

Vedolizumab for the treatment of chronic pouchitis
por: Travis, S, et al.
Publicado: (2023)

Introducing vedolizumab to clinical practice: who, when and how?
por: Bryant, R, et al.
Publicado: (2015)

Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn’s Disease
por: Eddie Y. Liu, et al.
Publicado: (2017-01-01)

Real-life treatment persistence and treatment outcomes of Finnish patients with inflammatory bowel disease receiving vedolizumab as first-line biological treatment
por: Tero Ylisaukko-oja, et al.
Publicado: (2024-06-01)

P571 Vedolizumab (VDZ) real-world outcomes in ulcerative colitis (UC)
por: Pulusu, S, et al.
Publicado: (2018)

Cytokine signature in convalescent SARS-CoV-2 patients with inflammatory bowel disease receiving vedolizumab
por: Simone Dallari, et al.
Publicado: (2024-01-01)

Vedolizumab for inflammatory bowel diseasesI
por: Igor L. Khalif, et al.
Publicado: (2018-08-01)

500 appetizers :
por: 331215 Blake, Susannah
Publicado: (2007)

500 soups :
por: 331215 Blake, Susannah
Publicado: (2007)

500 salads :
por: 331215 Blake, Susannah
Publicado: (2009)

Vedolizumab Safety During Pregnancy and Lactation in a Patient with Ulcerative Colitis: A Case Report
por: Pinto FPJ, et al.
Publicado: (2024-05-01)

Safety and efficacy of vedolizumab in pediatric inflammatory bowel disease with emphasis on the very-early-onset group
por: Sylwia Fabiszewska, et al.
Publicado: (2023-06-01)

COVID anomaly in the correlation analysis of S&P 500 market states.
por: M Mijaíl Martínez-Ramos, et al.
Publicado: (2024-01-01)

Comparison of the Efficacy of Vedolizumab and Ustekinumab in Biologic-naïve Patients with Moderately to Severely Active Crohn's Disease
por: LIU Liu, XU Wenhang, LYU Bin, FAN Yihong
Publicado: (2025-03-01)

International experience of vedolizumab in primary sclerosing cholangitis and inflammatory bowel disease
por: Williamson, K, et al.
Publicado: (2018)

24.500 Other Minds, Spring 2003
por: Byrne, Alex
Publicado: (2023)

500 Tricks : FLOORING MATERIALS AND OTHER FINISHES
Publicado: (2012)

Vedolizumab in Crohn Disease genesis-sefh drug evaluation report
por: Jenifer González Chávez, et al.
Publicado: (2015-09-01)

Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis
por: Beatriz Gros, et al.
Publicado: (2024-07-01)

Take vedolizumab home: transition from intravenous to subcutaneous treatment
por: Kaituo Huang, et al.
Publicado: (2024-05-01)

Effect of Ap-Index of Geomagnetic Activity on S&P 500 Stock Market Return
por: Lifang Peng, et al.
Publicado: (2019-01-01)

Short-term effectiveness and safety of ustekinumab and vedolizumab in elderly and non-elderly patients with Crohn’s disease: a comparative study
por: Lior Dar, et al.
Publicado: (2024-11-01)

Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials
por: Laurent Peyrin‐Biroulet, et al.
Publicado: (2024-03-01)

Curbing inappropriate C. difficile treatment in patients receiving concomitant laxatives
por: Paige Fields, et al.
Publicado: (2025-01-01)

Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases
por: Lynch, K, et al.
Publicado: (2019)

Vedolizumab treatment in a patient with X-linked agammaglobulinemia, is it safe and efficient?
por: Şükrü Çekiç, et al.
Publicado: (2019-12-01)

Data mining and analysis of adverse events of Vedolizumab based on the FAERS database
por: Qinyun Xu, et al.
Publicado: (2025-01-01)

3066 Real-world retrospective safety analysis of onabotulinumtoxina for the concomitant treatment of patients with spasticity and other therapeutic indications
por: Angeli Mayadev, et al.
Publicado: (2024-08-01)

Evaluating Efficacy of Vedolizumab, Ustekinumab, and Golimumab in the Management of Inflammatory Bowel Disease and the Combined Role of Nutritional Therapy with Biologics: A Review
por: Shahed Kamal, et al.
Publicado: (2024-08-01)

Predictors of Pancreatitis Among Patients with Inflammatory Bowel Disease Treated with Vedolizumab: Observation from a Large Global Safety Database
por: Joe F. Wernicke, et al.
Publicado: (2023-09-01)